Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions
Hematopoietic Stem Cell Transplantation
Interventions
DRUG

ATLG

5 mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.

DRUG

ATLG

7.5mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.

Trial Locations (5)

271000

Tai'an City Central Hospital, Taian

350001

Fujian Medical University Union Hospital, Fuzhou

400000

The Southwest Hospital of Amu, Chongqing

610083

People's Liberation Army The General Hospital of Western Theater Command, Chengdu

1340000

The First Bethune Hospital of Jilin University, Jilin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER